



Recombinant Protein Technical Manual
Recombinant Human BCMA/TNFRSF17 Protein (His
Tag)
RPES4027

Product Data:

Product SKU: RPES4027

Size: 10µg

Species: Human

Expression host: P. Pichia

Uniprot: Q02223

Protein Information:

Molecular Mass: 6.9 kDa

AP Molecular Mass: 12&15-28 kDa

Tag: C-His

Bio-activity:

Purity: > 90% as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg as determined by the LAL method.

Storage: Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Formulation: Lyophilized from a 0.2 µm filtered solution of PBS, pH7.4.

Reconstitution: Please refer to the printed manual for detailed information.

Application:

Synonyms: Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269; TNFRSF17; BCM; BCMA

Immunogen Information:

Sequence: Met1-Ala54

Background:

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.